

Original Research Article

Effect of Nuangong zhitong decoction on primary dysmenorrhea in mice

Ya-Zhen Xie¹, Jian-Qiang Qian¹, Qi-Bin Lu^{2*}

¹Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Taicang 215499, ²Department of Gynaecology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China

*For correspondence: **Email:** xyz8102@sina.com; **Tel:** +86 25 8661 7141

Sent for review: 20 May 2019

Revised accepted: 18 October 2019

Abstract

Purpose: To investigate the therapeutic effect of Nuangong Zhitong decoction (NZD) on primary dysmenorrhea (PD) in mice, and its mechanism of action.

Methods: Dysmenorrhea was established in female PD mice by intraperitoneal injection of oxytocin following estradiol benzoate pretreatment. The effects of NZD and its active principles (cinnamic aldehyde and cinnamic acid) on PD were determined using body twist method. Serum levels of prostaglandin E2 (PGE2) and prostaglandin F2 alpha (PGF2α) in mice were measured using ELISA.

Results: The results showed that NZD dose-dependently reduced oxytocin-induced writhing responses ($p < 0.05$). Moreover, cinnamic aldehyde and cinnamic acid reduced oxytocin-induced writhing responses in a concentration-dependent manner, with maximal inhibitions of 65.01 and 70.67 %, respectively, and also decreased serum levels of PGE2 and PGF2α in PD mice ($p < 0.05$).

Conclusion: These results indicate that NZD mitigates oxytocin-induced uterine tetanic contraction in mice. Thus, NZD has a potential for development into an anti-dysmenorrheal drug for use in humans.

Keywords: Nuangong Zhitong decoction, Prostaglandin, PGE2, PGF2α, Primary dysmenorrhea

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

INTRODUCTION

Dysmenorrhea is one of the most common gynecological symptoms caused by uterine contractions, with serious effects on quality of life of patients [1]. There are two types of dysmenorrhea: primary dysmenorrhea (PD) and secondary dysmenorrhea (SD). Primary dysmenorrhea refers to recurrent menstrual cramps that are not due to other diseases. In contrast, secondary dysmenorrhea refers to menstrual cramping pain caused by an organic pathology, such as endometriosis, adenomyosis

and uterine fibroids [1,2]. Primary dysmenorrhea occurs in up to approximately 50 % of menstruating females reportedly suffer from PD. The pain associated with PD is extremely severe in 15 % patients, and results in psychological distress such as anxiety and depression [2]. Moreover, the pain in PD is accompanied by nausea, vomiting, fatigue, and even diarrhea [3]. Currently, the main pharmacological treatments for PD include oral contraceptives or non-steroidal anti-inflammatory drugs (NSAIDs) [1,4]. However, NSAIDs and oral contraceptives cause unwanted side effects [5]. As an

alternative, Chinese herbal medicine is used for treating PD due to its fewer adverse effects and lower recurrence, relative to pharmacological therapies [6-9].

Wen jing decoction is a traditional Chinese prescription that widely applied in clinical treatment of dysmenorrhea [10]. *Nuangong zhitong* decoction (NZD) was developed from *Wen jing* decoction and is composed of *Cinnamomi ramulus*, evodiamine, asarum, *Radix linderae* and *Rhizoma corydalis* at ratio of 1:2:1:2:2. Cinnamic Cinnamaldehyde and cinnamic acid, two major constituents of *Cinnamomi ramulus*, have been reported to suppress oxytocin-induced uterine contractions [11,12]. Other components of NZD such as evodiamine, asarum, *Radix linderae* and *Rhizoma corydalis* warm the meridians and dissipate cold.

The aim of this study was to investigate the therapeutic effect of NZD on PD, and the underlying mechanisms in a PD model mice.

EXPERIMENTAL

Chemicals, reagents and animals

Estradiol benzoate was purchased from MedChemExpress (NJ, USA). Oxytocin was purchased from SPH No1 Biochemical and Pharmaceutical Co., Ltd (Shanghai, China). *Yueyueshu* was purchased from Zhong Jing Wan Xi Pharmaceutical Co. Ltd (Henan, China). Prostaglandin 2 ELISA Kit was purchased from R&D Systems, Inc (MN, USA), while PGF2 α ELISA Kit was product of Cayman Chemical Company (MI, USA). Female KM mice (25 \pm 5 g, 6 – 8-week-old) were obtained from Cavens Laboratory Animal Co., Ltd (Changzhou, China). All experiments were approved by Ethics Committee of Taicang Hospital of traditional Chinese Medicine.

Preparation of *Nuangong zhitong* decoction and its active principle components

Nuangong zhitong decoction was composed of 10 g of *cinnamomi ramulus*, 5 g of evodiamine, 3 g of asarum, 10 g of *Radix linderae* and 10 g of *Rhizoma corydalis*. The herbs were mixed and decocted with 2000 mL of water for 30 min. The decoction was performed twice to maximize NZD extract yield, and the extract was concentrated and filtered through a membrane filter to obtain NZD at a concentration of 1g/mL. Cinnamic aldehyde and cinnamic acid (Shanghai Yuan Ye Biotechnology Co., Ltd (Shanghai, China) were

dissolved in DMSO and diluted with normal saline prior to use.

Animal experiments

Asthenia cold type mice model was established through intragastric administration of a 4 g/mL decoction made from gypsum, gentiana, *Phelladendron chinensis* and *Rhizoma anemarrhena* (mixed in a ratio of 2:1.2:1:1.5) to 50 Balb/c mice for 14 days. The mice were then subcutaneously injected with estradiol benzoate (2 mg/kg) daily for 12 days so as to improve the sensitivity of the mice uterine tissues to oxytocin. On the 12th day, the mice were intraperitoneally injected with oxytocin (20 U/kg) to induce severe uterine contraction. Seven days after establishment of PD model, the mice were randomly divided into 5 groups (10 mice/group). One group received *yueyueshu* (1 g/kg; positive control group), while another group was given normal saline (PD group). The other 3 were NZD groups: low dose NZD group (3 g/kg), medium dose NZD group (9 g/kg), and high dose NZD group (30.00 g/kg). All treatments lasted for 7 days. 10 Balb/c mice which were intragastrically administered normal saline for 13 days (0.1 mL/10 g) as normal control group. On the 13th day, writhing reaction was induced through intraperitoneal injection of oxytocin (33 U/kg).

Studies on the effects of components of NZD on PD followed the same design used for NZD. The mice were randomly divided into the following groups (10 mice/group): normal control group, PD group (normal saline), positive control group (*yueyueshu*, 1 g/kg), low dose cinnamic acid group (10.00 mg/kg), medium dose cinnamic acid group (20.00 mg/kg), high dose cinnamic acid group (40.00 mg/kg), low dose cinnamaldehyde group (10.00 mg/kg), medium dose cinnamaldehyde group (20.00 mg/kg), and high dose cinnamaldehyde group (40.00 mg/kg).

Writhing test

The mice were placed in a box and intraperitoneally injected with oxytocin. The number of writhes in 30 min was counted. Analgesia (A) was calculated as in Eq 1.

$$A (\%) = \{(P - N)/P\}100 \dots\dots\dots (1)$$

where P and N are the number of writhes in PD and NZD groups, respectively.

Enzyme-linked immunosorbent assay (ELISA)

Blood was collected from the eyeball of each mouse. Serum levels of PGE2 and PGF2 α were

measured using ELISA according to the kit's protocol.

Statistical analysis

SPSS 19.0 software (IBM Corp, Armonk, NY, USA) was used for statistical analysis. All data are expressed as mean \pm standard deviation (SD). The differences between two groups were analyzed by Student's t-test. One-way ANOVA was performed for comparisons of multiple groups. Values of $p < 0.05$ was deemed statistically significant.

RESULTS

Effect of NZD on writhing frequency

To evaluate the effect of NZD on PD, mouse model of PD was established using estradiol benzoate and oxytocin. As shown in Table 1, the writhing frequency of PD group was 60-fold higher than that of normal control group, indicating the successful establishment of PD model. Compared with PD group, the writhing frequency of NZD at all doses decreased significantly, with analgesia of 33.77, 35.24 and 69.49 %, respectively.

Effect of NZD on serum PGE2 and PGF2 α

As shown in Figure 1, the levels of serum PGE2 and PGF2 α were significantly increased in PD group. However, *nuangong zhitong* decoction reduced the serum levels of PGE2 and PGF2 α in a dose-dependent manner. Moreover, the magnitude of reduction was higher in PGE2 than in PGF2 α .

Effect of cinnamic acid and cinnamaldehyde on writhing frequency

As shown in Table 2, compared with PD group, the number of writhes of mice in the low dose

cinnamaldehyde group (10.00 mg/kg), medium dose cinnamaldehyde group (20.00 mg/kg) and high dose cinnamaldehyde group (40.00 mg/kg) were significantly decreased, and the percentage analgesia reached 19.43, 48.23 and 65.01, respectively. Cinnamic acid also significantly and dose-dependently suppressed writhing responses in PD mice, with percentage analgesia values of 27.38, 46.47 for low, medium and high dose mice groups, respectively.

Effect of cinnamic acid and cinnamaldehyde on serum PGE2 and PGF2 α levels

Cinnamic acid and cinnamaldehyde, at all doses, significantly reduced the level of PGE2 (Figure 2). Moreover, cinnamic acid and cinnamaldehyde dose -dependently reduced the level of serum PGF2 α . The level of reduction of PGE2 by cinnamic acid and cinnamaldehyde was significantly higher than that of PGF2 α .

DISCUSSION

In Traditional Chinese Medicine (TCM), PD is thought to result from uterine blockage by blood stasis [12]. Herbal medicine has been used for a long time for treating PD in China [13,14].




Figure 1: Decreased serum PGE2 and PGF2 α levels by NZD in PD mice. Data are presented as mean \pm SD (n = 10); ** $p < 0.01$ versus normal control group; ### $p < 0.01$ versus PD group

Table 1: Effect of NZD on writhing reaction and analgesia in PD mice (n = 10)

Group	Writhing frequency (30 min)	Analgesia (%)
Normal control	0.00 \pm 0.00	100.00
PD	61.30 \pm 9.56**	0.00
Positive control	23.40 \pm 13.60###	61.82
NZD low (3.00 g/kg)	40.60 \pm 19.69###	33.77
NZD medium (9.00 g/kg)	39.70 \pm 15.17###	35.24
NZD high (30.00 g/kg)	18.70 \pm 11.78###	69.49

** $P < 0.01$ versus normal control group; ### $p < 0.01$ versus PD group

Table 2: Decreased writhing reaction and increased analgesia by cinnamic acid and cinnamaldehyde in PD mice (n = 10)

Group	Writhing frequency (30 min)	Analgesia (%)
Normal control	0.00±0.00	100.00
PD	56.60±13.85 ^{**}	0.00
Positive control	20.4±11.82 ^{###}	63.95
Cinnamaldehyde (10 mg/kg)	45.60±6.57 [#]	19.43
Cinnamaldehyde (20 mg/kg)	29.30±10.48 [#]	48.23
Cinnamaldehyde (40 mg/kg)	19.80±7.87 ^{###}	65.01
Cinnamic acid (10 mg/kg)	41.10±7.46 ^{###}	27.38
Cinnamic acid (20 mg/kg)	30.3±10.13 ^{###}	46.47
Cinnamic acid (40 mg/kg)	14.60±10.37 ^{###}	70.67

^{**}P < 0.01 versus normal control group; [#]p < 0.05, ^{###}p < 0.01 versus PD group




Figure 2: Decreased serum PGE2 and PGF2α levels by cinnamic acid and cinnamaldehyde in PD mice. Results are presented as mean ± SD (n = 10); ^{**}p < 0.01 versus normal control group; ^{###}p < 0.01 versus PD group

Wenjing decoction is a traditional Chinese prescription used for the treatment of PD and first introduced by the Chinese sage Zhongjing Zhang in the book of *Jingui Yaolue*. The NZD used in the present study was developed from *wenjing decoction*. Compared with *Wenjing decoction*, NZD has added *asarum*, *Radix linderae* and *Rhizoma corydalis*, which increase its analgesic effect. A PD mice model in the present study was used to study the effect of NZD on PD and established via intraperitoneal injection of oxytocin.

The results obtained in this study showed that NZD concentration-dependently reduced

oxytocin-induced writhing response. The analgesic effect of high dose of NZD was similar to that of *yueyue shu*, a traditional Chinese prescription used for the treatment of PD. Cinnamic acid and cinnamaldehyde are the two major constituents of *Cinnamomi ramulus* in NZD. It has been reported that cinnamic acid and cinnamaldehyde suppress oxytocin-induced uterine contractions [11,12]. In this study, it was found that cinnamic acid and cinnamaldehyde significantly reduced oxytocin-induced writhing response. The analgesic effects of cinnamic acid and cinnamaldehyde in the high-dose groups were even better than those of NZD. These data indicate that cinnamic acid and cinnamaldehyde are the active principles in NZD. Since *nuangong zhitong* decoction consists of five herbs, the roles of the other herbal components need to be investigated.

Prostaglandins (PGs) which are produced and released during menstruation cause abnormal uterine contractions, and sensitize spinal neurons to pain [15]. Prostaglandin 2 and PGF2α, two naturally occurring PGs, are regarded as the most crucial pain factors in PD [16]. They increase uterine contractility by binding to their receptors on the spiral arterioles [16]. The present study demonstrated that mice exposed to oxytocin had elevated PGE2 and PGF2α levels, which were suppressed by NZD, suggesting that PGE2 and PGF2α pathways may be involved in the relaxant effect of NZD. Moreover, it was demonstrated that cinnamic acid and cinnamaldehyde suppressed the levels of PGE2 and PGF2α in oxytocin-exposed mice, indicating that cinnamic acid and cinnamaldehyde may suppress oxytocin-induced writhing responses via inhibition of the effects of PGE2 and PGF2α. Since cyclooxygenase (COX)

catalyzes the biosynthesis of PGs [17,18], there is need to investigate whether COX is involved in the relaxant effect of NZD. Previous studies have demonstrated that oxytocin receptor (OTR) is up-regulated in PD patients and contributes to uterine contractions by binding to oxytocin [19,20]. In addition, it has been known that uterine contraction could be induced by intracellular Ca^{2+} overload in the uterine smooth muscles, leading to the occurrence of PD [21, 22]. Further studies will also investigate whether OTR and Ca^{2+} signaling are involved in the relaxant effect of NZD.

CONCLUSION

The findings of the present study indicate that NZD concentration-dependently reduces oxytocin-induced writhing responses in mice. Moreover, *Nuangong zhitong* decoction suppresses oxytocin-induced writhing responses possibly through modulating the levels of PGE2 and PGF2 α . These findings suggest that NZD can potentially be used to treat PD in humans.

DECLARATIONS

Acknowledgement

This study was supported by Project of Taicang Science and Technology (no. TC2017YYJC03).

Conflict of interest

No conflict of interest is associated with this study.

Contribution of authors

We declare that this study was done by the authors named in this manuscript and all liabilities pertaining to claims relating its content will be borne by the authors. Qi-Bin Lu designed all the experiments and revised the manuscript. Ya-Zhen Xie and Jian-Qiang Qian performed the experiments, while Ya-Zhen Xie wrote the manuscript.

Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution,

and reproduction in any medium, provided the original work is properly credited.

REFERENCES

1. Suvitie P. Dysmenorrhea in teenagers. *Duodecim* 2017; 133: 285-291.
2. Rencz F, Pentek M, Stalmeier PFM, Brodsky V, Ruzsa G, Gradwohl E, Baji P, Gulacsi L. Bleeding out the quality-adjusted life years: Evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. *Pain* 2017; 158:2259-2267.
3. Payne LA, Rapkin AJ, Seidman LC, Zeltzer LK, Tsao JC. Experimental and procedural pain responses in primary dysmenorrhea: A systematic review. *J Pain Res* 2017; 10:2233-2246.
4. Bernardi M, Lazzeri L, Perelli F, Reis FM, Petraglia F. Dysmenorrhea and related disorders. *F1000Res* 2017; 6:1645.
5. Davis AR, Westhoff C, O'Connell K, Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls: A randomized trial. *Obstet Gynecol* 2005; 106:97-104.
6. Nazar H, Usmanghani K. Clinical evaluation to assess the safety and efficacy of coded herbal medicine "dysmo-off" versus allopathic medicine "diclofenac sodium" for the treatment of primary dysmenorrhea. *J Herb Pharmacother* 2006; 6:21-39.
7. Oya A, Oikawa T, Nakai A, Takeshita T, Hanawa T. Clinical efficacy of kampo medicine (japanese traditional herbal medicine) in the treatment of primary dysmenorrhea. *J Obstet Gynaecol Res* 2008; 34:898-908.
8. Yang L, Chai CZ, Yue XY, Yan Y, Kou JP, Cao ZY, Yu BY. Ge-gen decoction attenuates oxytocin-induced uterine contraction and writhing response: Potential application in primary dysmenorrhea therapy. *Chin J Nat Med* 2016; 14:124-132.
9. Lang L, Meng Z, Sun L, Xiao W, Zhao L, Xiong Z. Integrated metabonomic study of the effects of guizhi fuling capsule intervention on primary dysmenorrheal using rp-uplc-ms complementary with hplc-uplc-ms technique. *Biomed Chromatogr* 2018;32
10. Gao L, Jia C, Zhang H, Ma C: Wenjing decoction (herbal medicine) for the treatment of primary dysmenorrhea. A systematic review and meta-analysis. *Arch Gynecol Obstet* 2017; 296:679-689.
11. He DY, Dai SM. Anti-inflammatory and immunomodulatory effects of paeonia lactiflora pall., a traditional chinese herbal medicine. *Front Pharmacol* 2011; 2:10.
12. Sun L, Liu L, Zong S, Wang Z, Zhou J, Xu Z, Ding G, Xiao W, Kou J. Traditional chinese medicine guizhi fuling capsule used for therapy of dysmenorrhea via attenuating uterus contraction. *J Ethnopharmacol* 2016; 191:273-279.
13. Pirota M. Commentary on the cochrane review of chinese herbal medicine for dysmenorrhea. *Explore (NY)* 2008; 4:389-391.

14. Park KS, Park KI, Hwang DS, Lee JM, Jang JB, Lee CH. A review of *in vitro* and *in vivo* studies on the efficacy of herbal medicines for primary dysmenorrhea. *Evid Based Complement Alternat Med* 2014; 2014:296860.
15. Calesnick B, Dinan AM. Prostaglandins and nsoids in primary dysmenorrhea. *Am Fam Physician* 1987; 35:223-225.
16. Powell AM, Chan WY, Alvin P, Litt IF. Menstrual-pgf2 alpha, pge2 and txa2 in normal and dysmenorrheic women and their temporal relationship to dysmenorrhea. *Prostaglandins* 1985; 29:273-290.
17. Parent J, Villeneuve C, Fortier MA. Evaluation of the contribution of cyclooxygenase 1 and cyclooxygenase 2 to the production of pge2 and pgf2 alpha in epithelial cells from bovine endometrium. *Reproduction* 2003; 126:539-547.
18. Sales KJ, Jabbour HN. Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium. *Reproduction* 2003; 126:559-567.
19. Fuchs AR, Ivell R, Ganz N, Fields MJ, Gimenez T. Secretion of oxytocin in pregnant and parturient cows: Corpus luteum may contribute to plasma oxytocin at term. *Biol Reprod* 2001; 65:1135-1141.
20. Guo SW, Mao X, Ma Q, Liu X. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (otr) in women with symptomatic adenomyosis. *Fertil Steril* 2013; 99:231-240.
21. Wray S, Jones K, Kupittayanant S, Li Y, Matthew A, Monir-Bishty E, Noble K, Pierce SJ, Quenby S, Shmygol AV. Calcium signaling and uterine contractility. *J Soc Gynecol Investig* 2003; 10:252-264.
22. Wray S, Shmygol A. Role of the calcium store in uterine contractility. *Semin Cell Dev Biol* 2007; 18:315-320.